In a document, the regulatory body reported that the Committee for Medicinal Products for Human Use (CHMP) “recommended the authorization of an adapted bivalent vaccine targeting the BA.4 and BA.5 subvariants of omicron, in addition to the original strain of SARS-CoV-2 ”. The CHMP recommendation will be forwarded to the European Commission, which will make the final decision.
ADVERTISING
The new vaccine
- It is aimed at people at least 12 years of age who have received at least one vaccine against Covid-19.
- It is a new and “more effective” version of the Cominarty vaccine, from Pfizer/BioNTech.
The EMA warned earlier this month that new variants of coronavirus may appear this winter European, although he said that vaccines will protect the population against serious forms of the disease.
On its Twitter account, the regulatory agency shared this Monday (12) an explanatory post about the authorization process for booster vaccines, following a recommendation.
